The heartbeat of cardiovascular medicine and telemedicine

Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment

Sponsored
AGORACOM NEWS FLASH

BREAKING: Spyder Cannabis Receives Approval on Development Permit for its Flagship Cannabis Store in Calgary, Alberta

  • Received approval on their development permit for a flagship retail location in the heart of Calgary
  • Spyder has now been accepted by Alberta Health Services and will begin construction in the coming weeks.
  • This brings Spyder’s total retail to 6 locations across Ontario and Alberta, this number is expected to grow over the coming months.

Spdr logo large

Hub On AGORACOM / Read Release

Message: CardioComm Solutions' HeartCheck(TM) CardiBeat and Smart Phone App Enter Final Stage of FDA 510(k) Review

CardioComm Solutions' HeartCheck(TM) CardiBeat and Smart Phone App Enter Final Stage of FDA 510(k) Review

posted on Nov 23, 2018 09:15AM

Market Release of HeartCheck(TM) CardiBeat and GEMS(TM) Mobile Application Set For Early 2019

CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has completed its response to the USA Food and Drug Administration ("FDA") for additional information following the Company's filing of its premarket notification 510(k), Class II medical device clearance application for the HeartCheck™ CardiBeat and GEMS™ Mobile Application.

The 510(k) application started its 90 day Substantive Review by the FDA on June 8, 2018. The FDA requested additional information from the Company regarding the device July 27, 2018, which stops the clock on the Substantive Review time line. The countdown of the 90 days will restart upon the FDA accepting the Company's response to the requested additional information.

The FDA's request for additional information required external and independent third party testing for electromagnetic and electrostatic discharge compatibility. The FDA also requested data confirming the device's ability to record ECGs of equivalent clinical quality, as compared to ECGs recorded using conventional ECG electrode patches and ECG cables. CardioComm was provided a maximum of 180 days to reply to the FDA examiner. While the Company intended to respond to the FDA within 90 days, the requested testing and documentation through third parties did not allow a response to the FDA to be completed within this time frame. All device tests have now been passed and results compiled for the reply to the FDA. The Substantive Review clock will restart once the FDA receives and accepts the Company's reply. Based on the FDA's published timelines, the Company projects a possible completion of the 510(k) application review by the end of December 2018. The Company notes that the FDA has the ability to request more time to complete their review at the FDA's discretion.

The HeartCheck™ CardiBeat is the second of several planned Bluetooth-enabled ECG recording devices to be marketed by the Company. The first was the Bluetooth HeartCheck™ECG PEN. As indicated in the Company's May 22, 2018 press release, the GEMS™ Mobile Smartphone app will have compatibility with a number of different wireless ECG recording devices, including wireless 12 lead devices which will have direct applicability to remote patient monitoring and telemedicine markets.

The Company will provide updates on this and future 510(k) applications. To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. Refer to the Company's May 22, 2018 press release for further information respecting the initial FDA filing.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share
New Message
Please login to post a reply